期刊文献+

拉米夫定对乙肝肿瘤标志物的临床研究 被引量:1

下载PDF
导出
摘要 目的探讨乙型肝炎病毒肿瘤标志物及肝癌的发病关系。方法笔者研究了60例大三阳乙肝患者。30例用拉米扶定治疗,30例不用药治疗,观察2组肿瘤标志物的变化,采用并进行5 a后的长期随访。FQ-PCR方法检测血清HBV-DNA含量。结果①拉米扶定对AFP、AFU、r-QT,CEA四种肿瘤标志物浓度的降低明显优于非用药组。②长期随访(5 a后)对乙肝病毒标志物(HBVDNA)的降低,拉米扶定明显优于非用药组。③长期随访(5a后)拉米扶定的癌变率明显低于非用药组。结论拉米夫定可降低血清中肿瘤标志物的浓度,使血清HBVDNA浓度明显下降。血清肿瘤标志物的浓度与血清乙肝病毒标志物的浓度呈正相关,与肝细胞癌的发生率呈负相关。
作者 晋相林
机构地区 鄢陵县中医院
出处 《河南职工医学院学报》 2011年第6期694-695,共2页 Journal of Henan Medical College For Staff and Workers
  • 相关文献

参考文献3

二级参考文献14

  • 1Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl- beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother,2001,45:2495-2501. 被引量:1
  • 2Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology,2001,33:751-757. 被引量:1
  • 3Delaney WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother,2001,12:1-35. 被引量:1
  • 4Ogata N, Fujii K, Takigawa S, et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol,1999,59:270-276. 被引量:1
  • 5Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology,2003,125:292-297. 被引量:1
  • 6Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology,2001,33:1527-1532. 被引量:1
  • 7Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology,1999,30:567-572. 被引量:1
  • 8Sun J, Wang Z, Ma S, et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol,2005,75:391-398. 被引量:1
  • 9Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase asssociated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology, 1998,28:1669-1673. 被引量:1
  • 10Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology,2004,126:91-101. 被引量:1

共引文献23

同被引文献29

  • 1蔡芝芳,尚凤梅,赵文学,吕芳玲,张朝侠.拉米夫定治疗失代偿期乙肝肝硬化的临床研究[J].西安交通大学学报(医学版),2006,27(6):575-577. 被引量:7
  • 2WHO. Position paper: Hepatitis B [ Z ] , 2009. 被引量:1
  • 3EL -SERAGHB. Hepatocellular carcinoma [ J ]. N Engl J Med, 2011,365:1118 - 1127. 被引量:1
  • 4EL- SERAG HB. Epidemiology of viral hepatitis and hepatocellular carcinoma [ J ]. Gastroenterology, 2012, 142 (6) : 1264 - 1273. el. 被引量:1
  • 5NI YH, CHANG MH, WU Jia -feng, et al. Minimization of hepatitis B infection by a 25 - year Universal vaccination program[ J]. J Hepatol, 2012, 57 (4) : 730 - 735. 被引量:1
  • 6OTI" JJ, STEVENS GA, GROEGER J, et al. Global epidemiology of hepatitis B virus infection: New estimates of age- specific HBsAg seroprevalence and endemicity [ J ]. Vaccine, 2012, 30(12): 2212-2219. 被引量:1
  • 7KN LN, XING J, KLEVENS RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007[J]. Ann Intern Med, 2012, 156(4) : U33 - 271. 被引量:1
  • 8PAPATHEODORIDIS G, BUTI M, CORNBERG MA, et al. EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1) : 167 - 185. 被引量:1
  • 9LOK AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? [ J ]. J Gastroenterol Hepatol, 2011, 26(2): 221 -227. 被引量:1
  • 10SHEN Ying- chun, HSU C, CHENG CC, et al. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using Meta - Regression[ J]. Oncology, 2012, 82 (5) : 275 - 289. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部